CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Joseph Mikhael: ASCO 2017 Takeaways in Myeloma

Published: Mon, 26 Jun 2017 09:16:29 EDT
Myeloma expert Joseph Mikhael discusses the studies at ASCO 2017 that affected his practice.
Medscape Oncology

Gadolinium Contrast Agents and Brain Safety: Signal vs Noise

Published: Mon, 26 Jun 2017 09:15:47 EDT
Gadolinium deposits in brain tissue of patients who had multiple gadolinium-enhanced MRIs prompted an FDA review, which concluded that no restrictions were necessary. Practitioners remain cautious.
Medscape Radiology

When Drugs and Surgery Don't Work, an Option in Epilepsy

Published: Mon, 26 Jun 2017 09:15:15 EDT
Dr Wilner and epileptologist Dr Jobst discuss two recent studies reporting favorable results of neurostimulation in patients with intractable epilepsy.
Medscape Neurology
Displaying results 4-6 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Roche’s emicizumab cuts bleed rate by 87% in hemophilia A

Published: Mon, 26 Jun 2017 09:42:55 +0000
Roche has released a closer look at the data it hopes will propel hemophilia A drug emicizumab to blockbuster status. Emicizumab cut the bleed rate by 87% in patients with inhibitors to factor VIII and aced all the secondary endpoints, leaving lingering concerns about side effects as the main barrier between Roche and big sales.

Bluebird Bio rebuilds case for blood disorder gene therapy

Published: Fri, 23 Jun 2017 13:46:18 +0000
Bluebird Bio reported encouraging data on its revamped gene therapy for sickle cell disease and beta thalassemia this morning, but shares slipped 6% premarket on some unresolved issues.

Aveo soars as long-beleaguered cancer drug nears approval

Published: Fri, 23 Jun 2017 12:45:58 +0000
Aveo Pharmaceuticals’ troubled tivozanib is on the cusp of winning approval in Europe. Drug assessors in the region gave the thumbs-up to the tyrosine kinase inhibitor in kidney cancer, sending Aveo’s stock on a tear and teeing up its partner to bring the drug to market.
Displaying results 4-6 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top